Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02781805 · ClinicalTrials.gov registry record · Phase 1
Pilot Study of Bisphosphonates for Breast Cancer
A Phase 1 study, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02781805 is a Phase 1 study that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 6 participants.
The verdict
NCT02781805, a Phase 1 study, was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The goal of this study is to mechanistically define the potential anticancer activities of the osteoporosis bisphosphonate (BP) drug alendronate, and extend the analysis to learn novel information about the impact of BP on gamma delta (γδ) T cells in breast tissues as well as epithelial breast cell differentiation of high-risk women. To this end, we have designed a BP "window trial" to examine the effect of 1 - 3 weeks administration of alendronate on women at high-risk for breast cancer, at the level of immunosurveillance and mammary epithelial cell differentiation.
Interventions
- DRUG Alendronate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2016-08-05 |
| Est. Completion | 2018-12-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02781805
The ClinicalTrials.gov registry entry for NCT02781805 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alendronate is the first listed.
NCT02781805 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02781805 about?
NCT02781805 is a clinical study titled "Pilot Study of Bisphosphonates for Breast Cancer". The goal of this study is to mechanistically define the potential anticancer activities of the osteoporosis bisphosphonate (BP) drug alendronate, and extend the analysis to learn novel information about the impact of BP on gamma delta (γδ) T cells in breast tissues as well as epithelial breast cell ...
What is the current status of trial NCT02781805?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2016-08-05. Estimated completion is 2018-12-12.
What interventions are being tested in trial NCT02781805?
The interventions under investigation include: Alendronate (DRUG).
Who is sponsoring clinical trial NCT02781805?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.